Journal Home > Volume 5 , Issue 1
Journal of Neurorestoratology 2017, 5(1): 51-57 https://doi.org/10.2147/JN.S99014
Review | Open Access | Issue | Published: 23 February 2017

Clinical neurorestorative progresses in cerebral palsy

Show Author's Information Alok Sharma1( ),  Tongchao Geng2,  Hemangi Sane3,  Pooja Kulkarni3
Department of Medical Services & Clinical Research, NeuroGen Brain and Spine Institute, Mumbai, India
Department of Neurology, Yuquan Hospital, Tsinghua University, Beijing, People’s Republic of China
Department of Research and Development, Neurogen Brain and Spine Institute, Mumbai, India
Keywords:
brain, regenerative medicine, stem cell therapy, bone marrow, umbilical cord, neural cells
Cite this article:
Sharma A, Geng T, Sane H, et al. Clinical neurorestorative progresses in cerebral palsy. Journal of Neurorestoratology, 2017, 5(1): 51-57. https://doi.org/10.2147/JN.S99014
Download citation
EndNote(RIS)
BibTeX

325

Views

9

Downloads

Citations

5

Crossref

7

WoS

0

Scopus

N/A

CSCD

Abstract Full text About this article

Cerebral palsy (CP), group of permanent nonprogressive clinical disorders in children, is caused by damage to the immature brain. Conventionally available treatments for CP are mainly targeted toward management of its symptoms. With the upcoming field of neurorestorative strategies, we are now able to repair the core brain damage in CP. There are various drugs, stem cells, etc, which have been implicated to have neurorestorative properties. Autologous bone marrow stem cells, umbilical cord stem cells, neural stem cells, and olfactory ensheathing cells have shown the safety and efficacy in preliminary studies. Here, we review the different medicines and cell types that have shown beneficial effects in clinical studies. We propose that combination strategies may be the future of neurorestoration.


menu
Abstract
Full text
Outline
About this article

Clinical neurorestorative progresses in cerebral palsy

Show Author's information Alok Sharma1( ), Tongchao Geng2, Hemangi Sane3, Pooja Kulkarni3
Department of Medical Services & Clinical Research, NeuroGen Brain and Spine Institute, Mumbai, India
Department of Neurology, Yuquan Hospital, Tsinghua University, Beijing, People’s Republic of China
Department of Research and Development, Neurogen Brain and Spine Institute, Mumbai, India

Abstract

Cerebral palsy (CP), group of permanent nonprogressive clinical disorders in children, is caused by damage to the immature brain. Conventionally available treatments for CP are mainly targeted toward management of its symptoms. With the upcoming field of neurorestorative strategies, we are now able to repair the core brain damage in CP. There are various drugs, stem cells, etc, which have been implicated to have neurorestorative properties. Autologous bone marrow stem cells, umbilical cord stem cells, neural stem cells, and olfactory ensheathing cells have shown the safety and efficacy in preliminary studies. Here, we review the different medicines and cell types that have shown beneficial effects in clinical studies. We propose that combination strategies may be the future of neurorestoration.

Keywords: brain, regenerative medicine, stem cell therapy, bone marrow, umbilical cord, neural cells

References(61)

1.
Carroll JE, Robert WM. Update on stem cell therapy for cerebral palsy. Expert Opin Biol Ther. 2011;11(4):463-471.
DOI Google Scholar
2.
Novak I, Hines M, Goldsmith S, Barclay R. Clinical prognostic messages from a systematic review on cerebral palsy. Pediatrics. 2012;130(5):e1285-e1312.
DOI Google Scholar
3.
Irazábal M, Marsà F, García M, et al. Family burden related to clinical and functional variables of people with intellectual disability with and without a mental disorder. Res Dev Disabil. 2012;33(3):796-803.
DOI Google Scholar
4.
Rosenbaum P, Paneth N, Leviton A, et al. A report: the definition and classification of cerebral palsy. Dev Med Child Neurol Suppl. 2007;109:8-14.
Google Scholar
5.
Lynn AK, Turner M, Chambers HG. Surgical management of spasticity in persons with cerebral palsy. PM R. 2009, 1(9):834-838.
DOI Google Scholar
6.
Cajal SRY. Degeneration and Regeneration of the Nervous System (translated by RM May). London: Oxford University Press; 1928.
7.
Wang Y, Gao B, Yang W. Clinical effect of oxiracetam capsules in the children suffering from cerebral palsy. Chin J Neuromed. 2007;4:409-411.
Google Scholar
8.
Izhbuldina GI. Changes in the hemostasis system and free-radical lipid oxidation in the acute stage of ischemic stroke in patients on neuroprotection treatment. Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(3 Pt 2):31-37.
Google Scholar
9.
Zhang C, Chopp M, Cui Y, et al. Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke. J Neurosci Res. 2010;88:3275-3281.
DOI Google Scholar
10.
Hassanein SM, Deifalla SM, El-Houssinie M, Mokbel SA. Safety and efficacy of cerebrolysin in infants with communication defects due to severe perinatal brain insult: a randomized controlled clinical trial. J Clin Neurol. 2016;12(1):79-84.
DOI Google Scholar
11.
Xiaoming L. Point injection of cerebrolysin in treatment of child cerebral palsy. Acta Acad Medicin Bengbu. 2004;29(4):331-332.
Google Scholar
12.
Rong X, Zhou W, Chen XW, Tao L, Tang J. Ganglioside GM1 reduces white matter damage in neonatal rats. Acta Neurobiol Exp. 2013;73:379-386.
Google Scholar
13.
Lee HS, Song J, Min K, et al. Short-term effects of erythropoietin on neurodevelopment in infants with cerebral palsy: a pilot study. Brain Dev. 2014;36(9):764-769.
DOI Google Scholar
14.
Jantzie LL, Miller RH, Robinson S. Erythropoietin signaling promotes oligodendrocyte development following prenatal systemic hypoxic-ischemic brain injury. Pediatr Res. 2013;74(6):658-667.
DOI Google Scholar
15.
Ohls RK, Kamath-Rayne BD, Christensen RD, et al. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo. Pediatrics. 2014;133(6):1023-1030.
DOI Google Scholar
16.
Kinney HC, Haynes RL, Xu G, et al. Neuron deficit in the white matter and subplate in periventricular leukomalacia. Ann Neurol. 2012;71(3):397-406.
DOI Google Scholar
17.
Khwaja O, Volpe JJ. Pathogenesis of cerebral white matter injury of prematurity. Arch Dis Child Fetal Neonatal Ed. 2008;93(2):F153-F161.
DOI Google Scholar
18.
Alvarez P, Carrillo E, Vélez C, et al. Regulatory systems in bone marrow for hematopoietic stem/progenitor cells mobilization and homing. Biomed Res Int. 2013;2013:312656.
DOI Google Scholar
19.
Gnecchi M, Zhang Z, Ni A, Dzau, VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res. 2008;103(11):1204-1219.
DOI Google Scholar
20.
Daadi MM, Davis AS, Arac A, et al. Human neural stem cell grafts modify microglial response and enhance axonal sprouting in neonatal hypoxic-ischemic brain injury. Stroke. 2010;41(3):516-523.
DOI Google Scholar
21.
Sharma S, Yang B, Strong R, et al. Bone marrow mononuclear cells protect neurons and modulate microglia in cell culture models of ischemic stroke. J Neurosci Res. 2010;88(13):2869-2876.
DOI Google Scholar
22.
Brenneman M, Sharma S, Harting M, et al. Autologous bone marrow mononuclear cells enhance recovery after acute ischemic stroke in young and middle-aged rats. J Cereb Blood Flow Metab. 2010;30(1):140-149.
DOI Google Scholar
23.
Bianco P, Riminucci M, Gronthos S, Robey PG. Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells. 2001;19(3):180-192.
DOI Google Scholar
24.
Sharma A, Gokulchandran N, Chopra G, et al. Administration of autologous bone marrow derived mononuclear cells in children with incurable neurological disorders and injury is safe and improves their quality of life. Cell Transplant. 2012;21(Suppl 1):S1-S12.
DOI Google Scholar
25.
Sharma A. Stem Cell Therapy in Neurological Disorders. Mumbai: NeuroGen Brain and Spine Institute; 2014.
26.
Sharma A, Kulkarni P, Sane H, et al. Positron emission tomography-computed tomography scan captures the effects of cellular therapy in a case of cerebral palsy. J Clin Case Rep. 2012;2:195.
DOI Google Scholar
27.
Sharma A, Sane H, Paranjape A, et al. Positron emission tomography - computer tomography scan used as a monitoring tool following cellular therapy in cerebral palsy and mental retardation - a case report. Case Rep Neurol Med. 2013;2013:141983.
DOI Google Scholar
28.
Purandare C, Shitole DG, Belle V, Kedari A, Bora N, Joshi M. Therapeutic potential of autologous stem cell transplantation for cerebral palsy. Case Rep Transplant. 2012;2012:825289.
DOI Google Scholar
29.
Mancías-Guerra C, Marroquín-Escamilla AR, González-Llano O, et al. Safety and tolerability of intrathecal delivery of autologous bone marrow nucleated cells in children with cerebral palsy: an open-label phase I trial. Cytotherapy. 2014;16(6):810-820.
DOI Google Scholar
30.
Chen G, Wang Y, Xu Z, et al. Neural stem cell-like cells derived from autologous bone mesenchymal stem cells for the treatment of patients with cerebral palsy. J Transl Med. 2013;11:21.
DOI Google Scholar
31.
Wang X, Cheng H, Hua R, et al. Effects of bone marrow mesenchymal stromal cells on gross motor function measure scores of children with cerebral palsy: a preliminary clinical study. Cytotherapy. 2013;15(12):1549-1562.
DOI Google Scholar
32.
Newcomb JD, Willing AE, Sanberg PR. Umbilical cord blood cells. Methods Mol Biol. 2009;549:119-136.
DOI Google Scholar
33.
Moise KJ. Umbilical cord stem cells. Obstet Gynecol. 2005;106(6):1393-1407.
DOI Google Scholar
34.
Chik KW, Chan PK, Li CK, et al. Human herpes virus-6 encephalitis after unrelated umbilical cord blood transplant in children. Bone Marrow Transplant. 2002;99:991-994.
DOI Google Scholar
35.
El-Cheikh J, Fürst S, Casalonga F, et al. JC virus leuko-encephalopathy in reduced intensity conditioning cord blood transplant recipient with a review of the literature. Mediterr J Hematol Infect Dis. 2012;4(1):e2012043.
DOI Google Scholar
36.
Papadopoulos KI, Low SS, Aw TC, Chantarojanasiri T. Safety and feasibility of autologous umbilical cord blood transfusion in 2 toddlers with cerebral palsy and the role of low dose granulocyte-colony stimulating factor injections. Restor Neurol Neurosci. 2011;29(1):17-22.
DOI Google Scholar
37.
Jensen A, Hamelmann E. First autologous cell therapy of cerebral palsy caused by hypoxic-ischemic brain damage in a child after cardiac arrest-individual treatment with cord blood. Case Rep Transplant. 2013;2013:951827.
DOI Google Scholar
38.
Wang L, Ji H, Zhou J, et al. Therapeutic potential of umbilical cord mesenchymal stromal cells transplantation for cerebral palsy: a case report. Case Rep Transplant. 2013;2013:146347.
DOI Google Scholar
39.
Luan Z, Liu W, Qu S, et al. Effects of neural progenitor cell transplantation in children with severe cerebral palsy. Cell Transplant. 2012;21(Suppl 1):S91-S98.
DOI Google Scholar
40.
Min K, Song J, Kang JY, et al. Umbilical cord blood therapy potentiated with erythropoietin for children with cerebral palsy: a double-blind, randomized, placebo-controlled trial. Stem Cells. 2013;31(3):581-591.
DOI Google Scholar
41.
Huang H, Chen L, Xi H, et al. Olfactory ensheathing cells transplantation for central nervous system diseases in 1,255 patients. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2009;23(1):14-20.
Google Scholar
42.
Fischer UM., Harting MT, Jimenez F, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: The pulmonary first-pass effect. Stem Cells Dev. 2009;18(5):683-691.
DOI Google Scholar
43.
Lim JY, Jeong CH, Jun JA, et al. Therapeutic effects of human umbilical cord blood-derived mesenchymal stem cells after intrathecal administration by lumbar puncture in a rat model of cerebral ischemia. Stem Cell Res Ther. 2011;2(5):38.
DOI Google Scholar
44.
Kondziolka D, Steinberg G, Wechsler L, et al. Neurotransplantation for patients with subcortical motor stroke: a phase 2 randomized trial. J Neurosurg. 2005;103:38-45.
DOI Google Scholar
45.
Shankaran S, Laptook AR, Ehrenkranz RA, et al. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. N Engl J Med. 2005;353:1574-1584.
DOI Google Scholar
46.
Rutherford MA, Azzopardi D, Whitelaw A, et al. Mild hypothermia and the distribution of cerebral lesions in neonates with hypoxic-ischemic encephalopathy. Pediatrics. 2005;116:1001-1006.
DOI Google Scholar
47.
Lei B, Tan X, Cai H, Xu Q, Guo Q. Effect of moderate hypothermia on lipid peroxidation in canine brain tissue after cardiac arrest and resuscitation. Stroke. 1994;25:147-152.
DOI Google Scholar
48.
Thoresen M, Penrice J, Lorek A, et al. Mild hypothermia after severe transient hypoxia-ischemia ameliorates delayed cerebral energy failure in the newborn piglet. Pediatr Res. 1995;37:667-670.
DOI Google Scholar
49.
Azzopardi DV, Strohm B, Edwards AD, et al. Moderate hypothermia to treat perinatal asphyxial encephalopathy. N Engl J Med. 2009;361:1349-1358.
DOI Google Scholar
50.
Gluckman PD, Wyatt JS, Azzopardi D, et al. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial. Lancet. 2005;365:663-670.
DOI Google Scholar
51.
Gonzalez-Ibarra FP, Varon J, Lopez-Meza EG. Therapeutic hypothermia: critical review of the molecular mechanism of action. Front Neurol. 2011;2:4.
DOI Google Scholar
52.
Gonzales-Portillo GS, Reyes S, Aguirre D, Pabon MM, Borlongan CV. Stem cell therapy for neonatal hypoxic-ischemic encephalopathy. Front Neurol. 2014;5:147.
DOI Google Scholar
53.
Mukherjee A, Raison M, Sahni T, et al. Intensive rehabilitation combined with HBO2 therapy in children with cerebral palsy: a controlled longitudinal study. Undersea Hyperb Med. 2014;41(2):77-85.
Google Scholar
54.
Lacey DJ, Stolfi A, Pilati LE. Effects of hyperbaric oxygen on motor function in children with cerebral palsy. Ann Neurol. 2012;72(5):695-703.
DOI Google Scholar
55.
Pérez-Gaxiola G. Hyperbaric oxygen did not improve symptoms in children with cerebral palsy. Arch Dis Child Educ Pract Ed. 2013;98(5):198.
DOI Google Scholar
56.
Sharma A, Sane H, Paranjape A, Gokulchandran N, Takle M, Badhe P. Seizures as an adverse event of cellular therapy in pediatric neurological disorders and its prevention. J Neurol Disord. 2014;2:164.
DOI Google Scholar
57.
Debuse D, Brace H. Outcome measures of activity for children with cerebral palsy: a systematic review. Pediatr Phys Ther. 2011;23(3):221-231.
DOI Google Scholar
58.
Bax M, Tydeman C, Flodmark O. Clinical and MRI correlates of cerebral palsy: The European Cerebral Palsy Study. JAMA. 2006;296(13):1602-1608.
DOI Google Scholar
59.
Li DK, Li MJ, Traboulsee A, Zhao G, Riddehough A, Paty D. The use of MRI as an outcome measure in clinical trials. Adv Neurol. 2006;98:203-226.
Google Scholar
60.
Spiriev T, Sandu N, Schaller B. Molecular imaging and tracking stem cells in neurosciences. Methods Mol Biol. 2013;1052:195-201.
DOI Google Scholar
61.
Sandu N, Momen-Heravi F, Sadr-Eshkevari P, Schaller B. Molecular imaging for stem cell transplantation in neuroregenerative medicine. Neurodegener Dis. 2012;9(2):60-67.
DOI Google Scholar
Publication history
Copyright
Rights and permissions

Publication history

Published: 23 February 2017
Issue date: December 2017

Copyright

© 2017 The Author(s).

Rights and permissions

© 2017 Sharma et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

Return